ValiRx Plc

Type: Company
Name: ValiRx Plc
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Market report: BHP demerger raises concerns

UK stocks rise for a fifth straight day on Tuesday, helped by easing geopolitical tensions in Ukraine. The FTSE 100 is nearly 0.5% higher at 6,775 in early trading, it’s highest level this month.Bucking that wider trend, investors in FTSE 100 mining giant ... [Published Shares Magazine - Aug 19 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 2 reports

ValiRx Narrows Half-Year Loss On Lower Costs, Progresses Pipeline

LONDON (Alliance News) - ValiRx PLC Tuesday announced a slightly narrowed pretax loss for the half-year to the end of June as it tightened operating expenses and continued to progress its pipeline of drug candidates.... ... [Published Town Hall - Aug 19 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

ValiRx happy with first half progress

Drug developer () is waiting for approval from the UK Ethics Committee to start recruitment for its first human trial of lead cancer treatment VAL201.The company ended the half year to June with cash equivalents of £0.76mln (2013: £1.17mln), which chairman ... [Published Proactive Investors.co.uk - Aug 19 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Tuesday's most followed: Just Eat, Serco, Prudential, Cloudbuy and German investor confidence

UK shares were holding their own Tuesday - just - and were up around a point as a host of corporate results were keeping fingers busy browsing the web for financial news. Outsourcing group Serco ( LON:SRP ) was one of the most followed stocks this morning ... [Published Proactiveinvestors United Kingdom RSS feed - Aug 12 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 3 reports

FTSE down as Intertek shines in tepid trade

StockMarketWire.com - FTSE indices closed down, blue chips and mid caps ailing, with falls in retail-related stocks offsetting gains among some mining and several financial stocks. Wall St was mixed. At the close, the FTSE 100 was down 1.66 points, or ... [Published Stock Market Wire - Aug 04 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 2 reports

|UPDATE - ValiRx gets MHRA approval for phase I/II cancer trial

-- adds broker target-- Shares is ValiRx ( LON:VAL ) shot higher as it confirmed Uk regulatory approval for a Phase I/II trial for its lead product that treats prostate cancer and other advanced solid tumours.  The trial will take place at University ... [Published Proactiveinvestors United Kingdom website - Aug 04 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 3 reports

VALIRX : Gets Authorisation For VAL201 Trials, Shares Jump

LONDON ( Alliance News ) - ValiRx PLC Monday said its request to run clinical trials for its VAL201 cancer treatment has been accepted by the UK's licensing authority.Shares in the group surged on the back of the news in early trade, up 11.2% to 0.378 ... [Published 4 Traders - Aug 04 2014]
First reported May 01 2014 - Updated May 01 2014 - 2 reports

ValiRx gets Japanese patent approval for NAV3 biomarker

ValiRx’s (LON:VAL) NAV3, a cancer screening test gene biomarker has recently received patent approval from the Japanese patent office (JPO).The granting of this latest patent means that ValiRx now has biomarker granted patent protection in Jap...Related ... [Published BioPortfolio - May 01 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 2 reports

Proactive news summary: InternetQ, AdEPT Telecom, ValiRx, Ncondezi Energy, Gemfields, ANGLE

Mobile marketing specialist InternetQ ( LON:INTQ ) had its target price hiked by Canaccord Genuity on Tuesday after impressive full-year figures. Adjusted EBITDA rose by a third to €16.2mln in 2013 from €12.2mln the year before on the back of a 42% ... [Published Proactiveinvestors United Kingdom RSS feed - Apr 08 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 5 reports

UPDATE ValiRx sets up joint venture to advance lung cancer drug

---adds broker comment and share price---ValiRx (LON:VAL) has set up a joint venture firm with Tangent Reprofiling to advance a treatment for lung cancer, for which the market is valued at around US$5 billion.ValiSeek has purchased the exclusive wo.. ... [Published BioPortfolio - Apr 08 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 2 reports

Most followed: AFC Energy, Advanced Comp, Barclays, Falkland Islands, Motive TV, Quindell, ValiRx

Aside from the latest twist in the LIBOR saga involving Barclays ( LON:BARC ), news on the blue-chips is sparse today. That leaves the stage open for the growth stocks, and one of the hottest stories of the morning has been the joint venture announced ... [Published Proactiveinvestors United Kingdom RSS feed - Apr 08 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 2 reports

Q&A ValiRx looks forward to clinical trials

Related Biotechnology, Pharmaceutical and Healthcare NewsProactive Investors (PI) interviewed the management of the cancer drug treatment developer to find out about future plans.Original Article: Q&A: ValiRx looks forward to clinical trialsNEXT ARTICLE ... [Published BioPortfolio - Apr 01 2014]

Quotes

de Giorgio-Miller added: "We have made substantial progress during this period and are very pleased to see both VAL201 now making its way down the regulatory pathway and our portfolio of drug candidates enhanced and enlarged."
Broker Investec kept a 'sell' strance and said: "The turnaround story is potentially becoming more interesting, but equally we do not think this will be an overnight success." it commented
A welcome return to core growth by financial trading software supplier Fidessa (FDSA) was wiped out by stiff currency headwinds. It warned that "we believe it is likely to be a factor for the remainder of the year." Early gains reversed to see a 0.15% rise to 2059p
...the Chief Executive of ValiRx , said he was "thrilled that the VAL201 clinical development has now entered the human patient phase" and said he is "looking forward to receiving information about the compound's performance and behaviour in this critical stage of development."

More Content

All (53) | News (49) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Market report: BHP demerger raises concerns [Published Shares Magazine - Aug 19 2014]
ValiRx Narrows Half-Year Loss On Lower Costs, P... [Published Town Hall - Aug 19 2014]
Alecto Minerals to brief investors at first eve... [Published MoneyAM - Aug 19 2014]
ValiRx happy with first half progress [Published Proactive Investors.co.uk - Aug 19 2014]
ValiRx HY Loss Narrows [Published RTTNews.com - Aug 19 2014]
Tuesday's most followed: Just Eat, Serco, Prude... [Published Proactiveinvestors United Kingdom RSS feed - Aug 12 2014]
FTSE down as Intertek shines in tepid trade [Published Stock Market Wire - Aug 04 2014]
Equities Research Analysts’ Ratings Reiteration... [Published American Banking News - Aug 04 2014]
Market report: Investors ditch Telecity [Published Shares Magazine - Aug 04 2014]
FTSE mixed as miners, financials help blue chips [Published Telegraph - Aug 04 2014]
|UPDATE - ValiRx gets MHRA approval for phase I... [Published Proactiveinvestors United Kingdom website - Aug 04 2014]
VALIRX : Gets Authorisation For VAL201 Trials, ... [Published 4 Traders - Aug 04 2014]
ValiRx – Notice of Acceptance of Request for CT... [Published Noodls - Aug 04 2014]
ValiRx gets MHRA approval for phase I/II cancer... [Published Proactiveinvestors United Kingdom RSS feed - Aug 04 2014]
ValiRx PLC : Notice of Acceptance of CTA Request [Published Investegate - Aug 04 2014]
Prostate Cancer - Pipeline Review, H1 2014 - Ne... [Published SBWire - Jul 14 2014]
Broker spotlight: Stagecoach, ASOS, Sports Dire... [Published Proactiveinvestors United Kingdom website - Jun 10 2014]
ValiRx lead treatment moves to human stage canc... [Published Proactiveinvestors United Kingdom RSS feed - Jun 10 2014]
Proactive news summary: Antrim Energy, Caza, Fa... [Published Proactiveinvestors United Kingdom RSS feed - May 15 2014]
US equities continue their slide [Published Proactiveinvestors United Kingdom RSS feed - May 15 2014]
ValiRx pleased with new joint venture's early p... [Published BioPortfolio - May 15 2014]
ValiRx gets Japanese patent approval for NAV3 b... [Published BioPortfolio - May 01 2014]
ValiRx gets Japanese patent approval for NAV3 b... [Published Proactiveinvestors United Kingdom RSS feed - May 01 2014]
Upgrade hints at ValiRx's significant potential [Published Proactiveinvestors United Kingdom RSS feed - Apr 14 2014]
Proactive news summary: InternetQ, AdEPT Teleco... [Published Proactiveinvestors United Kingdom RSS feed - Apr 08 2014]
UPDATE ValiRx sets up joint venture to advance... [Published BioPortfolio - Apr 08 2014]
UPDATE - ValiRx sets up joint venture to advanc... [Published Proactiveinvestors United Kingdom RSS feed - Apr 08 2014]
Most followed: AFC Energy, Advanced Comp, Barcl... [Published Proactiveinvestors United Kingdom RSS feed - Apr 08 2014]
UKs ValiRx forms joint venture to fast track lu... [Published BioPortfolio - Apr 08 2014]
Most followed: AFC Energy, Advanced Comp, Barcl... [Published Proactiveinvestors United Kingdom RSS feed - Apr 08 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
|UPDATE - ValiRx gets MHRA approval for phase I... [Published Proactiveinvestors United Kingdom website - Aug 04 2014]
-- adds broker target-- Shares is ValiRx ( LON:VAL ) shot higher as it confirmed Uk regulatory approval for a Phase I/II trial for its lead product that treats prostate cancer and other advanced solid tumours.  The trial will take place at University ...
Broker spotlight: Stagecoach, ASOS, Sports Dire... [Published Proactiveinvestors United Kingdom website - Jun 10 2014]
You wait ages for a broker note on buses and train operators and two turn up at once. Deutsche Bank expects this year to continue to be dominated by rail re-franchising awards.  So far this year Thameslink has been awarded to Govia (from FirstGroup ...
ValiRx sets up joint venture to advance lung ca... [Published Proactiveinvestors United Kingdom website - Apr 08 2014]
ValiRx ( LON:VAL ) has set up a joint venture firm with Tangent Reprofiling Ltd to advance a treatment for lung cancer, for which the market is valued at around US$5 billion. ValiSeek has purchased the exclusive worldwide licence for the drug VAL401 ...
ValiRx says annual results show the company is ... [Published Proactiveinvestors United Kingdom website - Mar 26 2014]
George Morris, chief operating officer of ValiRx ( LON:VAL ) tells Proactiveinvestors the company's annual results show the company is 'making progress'. ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.